SGMO
SANGAMO THERAPEUTICS, INC
Key Financials
Net Income
$-122932000
↓ 25.5%
Revenue
$39.6M
↓ 31.6%
Operating Income
$-121239000
↓ 16.6%
EPS (Diluted)
$-0.44
↑ 10.2%
Total Assets
$59.7M
↓ 41.2%
Total Liabilities
$74.0M
↓ 6.2%
Shareholders' Equity
$-14268000.00
↓ 162.7%
Cash & Equivalents
$20.9M
↓ 50.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/21/2026 | View on SEC |
| 8-K | 9/8/2026 | View on SEC |
| 8-K | 8/28/2026 | View on SEC |
| NT 10-Q | 8/17/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| 8-K | 7/20/2026 | View on SEC |
| 8-K | 7/1/2026 | View on SEC |
| 8-K/A | 6/23/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SGMO |
| Company Name | SANGAMO THERAPEUTICS, INC |
| CIK | 1001233 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 5109706000 |